MedTrace Logo

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

NCT07752550 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-08-07

No results posted yet for this study

Summary

To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG

Retlirafusp alfa+Nab-paclitaxel:

Retlirafusp alfa+Nab-paclitaxel

DRUG

Retlirafusp alfa+Fluzoparib

Retlirafusp alfa+Fluzoparib

DRUG

Retlirafusp alfa+TP-AC

Retlirafusp alfa+TP-AC

DRUG

Retlirafusp alfa+Fluzoparib

Retlirafusp alfa+Fluzoparib

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2028-07-30
Completion
2029-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07752550 on ClinicalTrials.gov